Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Investment Management Corp of Ontario

Investment Management Corp of Ontario raised its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 125.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 24,546 shares of the company's stock after acquiring an additional 13,678 shares during the quarter. Investment Management Corp of Ontario's holdings in Moderna were worth $1,021,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB increased its position in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Compass Planning Associates Inc purchased a new stake in shares of Moderna during the fourth quarter worth approximately $37,000. Venturi Wealth Management LLC grew its holdings in Moderna by 286.2% in the 4th quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after buying an additional 664 shares in the last quarter. Crowley Wealth Management Inc. purchased a new stake in Moderna in the 4th quarter valued at $41,000. Finally, Itau Unibanco Holding S.A. grew its holdings in Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after buying an additional 343 shares in the last quarter. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on MRNA. Citigroup began coverage on Moderna in a research note on Thursday, March 13th. They issued a "neutral" rating and a $40.00 price target on the stock. Evercore ISI decreased their price target on Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group lowered Moderna from a "buy" rating to a "neutral" rating and decreased their price target for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Thursday, April 17th. Finally, Royal Bank of Canada decreased their price target on Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Moderna currently has a consensus rating of "Hold" and an average price target of $53.95.

Moderna Stock Performance

Moderna stock traded up $1.21 during midday trading on Friday, reaching $24.86. The company's stock had a trading volume of 14,835,486 shares, compared to its average volume of 7,780,843. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $170.47. The stock's 50 day simple moving average is $27.87 and its 200 day simple moving average is $35.44. The firm has a market capitalization of $9.61 billion, a PE ratio of -2.68 and a beta of 1.99.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. The company had revenue of $108.00 million for the quarter, compared to the consensus estimate of $130.35 million. Moderna had a negative return on equity of 28.74% and a negative net margin of 110.04%. Moderna's quarterly revenue was down 35.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($3.07) earnings per share. Equities analysts predict that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.